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Primary hepatocellular carcinoma is the most common form of
primary liver malignancy (Bain and MC Master, 1997; Johnson,
1997), and is among the 10 most common tumours (Sherman,
1995; Duvoux, 1998) in the world. In China, it is a main fatal
malignancy. The annual morbidity is at least about 100 000 and
the mortality 110 000 in China (Fujimoto et al, 1994). Chronic
hepatitis B or C viral infection appears to be the most important
risk factor for HCC (Wallner et al, 1994). Also, chemical carcino-
gens (e.g. aflatoxins and mycotoxins), haemochromatosis and
other chronic liver diseases have proved to be closely associated
with HCC in China (Fujimoto et al, 1994; Xu et al, 1996). During
the long period of chronic liver lesion, inflammation and liver cell
turnover, hepatocyte genomic errors accumulate and HCC eventu-
ally develop as an end-stage of the chronic liver disease. The
molecular events for HCC development are very complex, and
HCC has proved to be genetically heterogenous neoplasms (Hui
and Makuuchi, 1999; Kondoh et al, 1999; Schlott et al, 1999).
There have been at least 30 species of related genes cloned and
characterized, and such findings are still increasing (Irene, 1998;
Ozturk, 1999). The known genes include several growth factors
and their receptors, cell cycle regulators, oncogenes and tumour
suppressor genes (Hui and Makuuchi, 1999). But to date, the iden-
tified genes have not yet fully disclosed the mechanisms of HCC
(Johnson, 1997; Hui and Makuuchi, 1999). Theoretically, there
should still be many other genes involved in the development of
HCC. 
In the attempt to identify HCC-susceptible genes, differential
display method was employed in this study (Liang and Pardee,
1992; Liang et al, 1993; Zhang et al, 1996). For an analysis of
altered expression genes between HCC tissues and their
surrounding liver tissues, we isolated a novel gene termed HCCA2
with a full length of cDNA. We compared HCCA2 expression in
HCC with the pathological parameters to probe its potential
biological role. Also, we raised antibodies for HCCA2 and investi-
gated its immunohistochemical characterization. 
MATERIALS AND METHODS 
Patients and specimens 
Primary hepatocellular carcinoma and their corresponding
noncancerous liver tissues were obtained from 43 patients who
had received surgical resection at the Eastern Hepatobilliary
Surgical Hospital of The Second Military Medical University,
Shanghai, China. No patients had received preoperative or adju-
vant chemotherapy or radiotherapy. Maximum tumour diameter
was measured macroscopically in fresh specimens. For RNA
analysis, HCC tissues and surrounding liver tissues were sepa-
rately cut and stored in liquid nitrogen immediately after surgery.
These included 42 male and 1 female patients with a median age of
50 years (range 24–72 years). 36 (83.7%) patients had serological
evidence of hepatitis B virus infection. The serum AFP level was
above 25 µ g L-1 in 24 cases (55.8%). The tumour size was smaller
than 5 cm (small HCC) in 13 patients and larger than 5 cm in
30. Histologically, 41 patients (95.3%) were accompanied
by cirrhosis. The 43 tumours comprised 5 well differenti-
ated (Edmondson’s grades I & II) and 38 poorly differentiated
(Edmondson’s grades III & IV) HCCs. Macroscopic portal vein
tumour spread was found in 3 patients, and microscopic
surrounding liver vascular cancer thrombi were found in 26. Gross
and microscopic intrahepatic adjacent small satellite nodule
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lesions were found in 30, and tumour capsule invasion of liver
cancer was founded in 31 (Table 1). Fetal tissues of liver and brain
and lung and spleen were obtained from fetuses and newborns
during autopsy. Adult normal tissues were obtained from a healthy
young man having died of a traffic accident. 
RNA extraction and differential display 
Total RNA of human HCC tissues and the paired non-tumourous
liver from each patient, and from a series of normal adult tissues
and fetal tissues was extracted by the guanidinium isothiocyanate
extraction method (Chomczinski and Sacchi, 1987). The differen-
tial display method was performed as described previously (Liang
and Pardee, 1992; Liang et al, 1993; Zhang et al, 1996). DDPCR
fragments were then reamplified by the same primers of the
anchoring oligo (dT) primer T12CA (5′ -TTTTTTTTTTTTCA-3′ )
and an arbitrary 10-base olignucleotide A2 (5′ -AATCGGGCTG-
3′ ), separated on a 1.6% argarose gel, purified by QIAEX II gel
extraction kit (QIAGEN, Hilden, Germany), and subcloned into
the pGEM-T vector (Promega, Madison, WI, USA) using standard
molecular cloning techniques. 
Library screening and nucleotide sequencing 
To obtain the cDNA in full length, the fragment of interest
contained in the PCR clone (length in 582 base pairs) was used as
a probe in the screening of human placental cDNA library
(Clontech), using the standard filter hybridization techniques
described (Wang et al, 1996, 1998). At the end of the third
screening, we got 12 plaques containing the target nucleotide
sequence. We sent the plaque which contained the longest DNA
sequence for a test of its sequence on an ABI automated DNA
Table 1 Details of HCCA2 expression in 43 cases of hepatocellular carcinoma 
Case Tumour Tumour Serum Histology of Capsule Cancer Satellite ki-67 
no. Sex Age (yr) size (cm) differentiation AFP HBsAg non-tumourous liver invasion thrombi lesion protein HCCA2 
1 M 65 6 Poor 3.3 – Cirrhosis + + –– + 
2 M 42 8.2 Poor >1000 + Cirrhosis – ++––  
3 M 38 9 Poor >1000 + Cirrhosis –– ++ +  
4 M 64 16 Poor 5.9 – Cirrhosis – +++ +  
5 M 66 4 Well 8.9 + Cirrhosis –– – – –  
6 M 28 4 Poor 7.7 + Cirrhosis + + + – + 
7 M 61 5 Poor 0.4 – Normal + – ++ +  
8 M 60 10 Poor >1000 – Cirrhosis + + + + + 
9 M 62 11 Well >1000 – Cirrhosis + – + – + 
10 M 51 8 Poor >1000 + Cirrhosis + + + + + 
11 M 41 8 Poor >1000 + Cirrhosis + ––++  
12 M 46 4.2 Poor 9.6 + Cirrhosis + + – ++  
13 M 65 7.4 Well 6 – Normal – + – + – 
14 M 24 12 Poor 37.7 + Cirrhosis + + + + + 
15 M 43 5 Poor 414 + Cirrhosis + +* + + + 
16 M 50 25 Poor 122.9 + Cirrhosis + + + + + 
17 M 57 6 Poor 215 + Cirrhosis + + + + +a
18 M 37 12 Poor 810 + Cirrhosis + + – ++  
19 M 58 10 Poor >1000 + Cirrhosis + + + + + 
20 M 47 8 Poor 9.8 + Cirrhosis + +* + + + 
21 M 54 3.9 Poor 6.0 + Cirrhosis –– + ––  
22 M 49 10.3 Poor >1000 + Cirrhosis + + + + – 
23 M 49 6.9 Poor 33.9 + Cirrhosis – ++––  
24 M 51 4 Well 28.9 + Cirrhosis –– – – –  
25 M 49 5 Poor 211 + Cirrhosis + – + – + 
26 M 54 15 Poor >1000 + Cirrhosis –– – ++  
27 M 33 9 Poor 7.6 + Cirrhosis + + + + + 
28 M 40 5 Poor 3.1 + Cirrhosis + + + + + 
29 M 69 6 Poor 44.2 + Cirrhosis – ++––  
30 M 44 12 Poor >1000 + Cirrhosis + – ++ +  
31 M 45 10 Poor >1000 + Cirrhosis + – ++ +  
32 M 44 4.2 Poor 8.8 + Cirrhosis + ––++  
33 M 39 3.5 Poor 3.9 + Cirrhosis + – ++ +  
34 M 41 4.5 Poor 16.3 – Cirrhosis + + + + – 
35 M 44 9 Poor 6.3 + Cirrhosis + ––++  
36 F 65 6 Poor >1000 + Cirrhosis + + + + + 
37 M 55 7 Poor >1000 + Cirrhosis + +* + + +a
38 M 52 9 Poor >1000 + Cirrhosis –– – ++  
39 M 51 9.2 Poor >1000 + Cirrhosis + + + + + 
40 M 48 4 Poor 23 + Cirrhosis – +++ +  
41 M 64 9 Poor 8.5 + Cirrhosis + + + + + 
42 M 58 9 Well 14.3 + Cirrhosis + ––++  
43 M 72 6.5 Poor 25 + Cirrhosis + ––++  
M = Male, F = Female; AFP, α -fetoprotein in µ g l–1; HBsAg, hepatitis B surface antigen; *had macroscopic portal vein tumour thrombi; ahad low levels expression
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sequencing system (Applied Biosystems, Foster City, CA), using
the ABI Prism DNA sequencing kit with 2 different sets of
primers. Multiple sequences were obtained in both orientations. 
Northern blot assay 
40 µ g of total RNA was used for Northern blot analysis (Wang
et al, 1996, 1998). The probe of 2 µ g HCCA2 full-length cDNA
was labelled with 50 µ Ci  α -32P-dATP using Prime-a-Gene kit
(Promega, Madison, WI, USA) according to the given protocol.
The blot was exposed to X-ray film for 10 days at –80˚C. In order
to calibrate relative quantities of loaded RNAs, the blot was
rehybridized with a cDNA probe of the β -actin gene. 
Preparation of antisera 
The C-terminal 160 amino acids (residues 1812 to 2292) were
subcloned into the fusion expression vector pGEX-5X-1
(Pharmacia Biotech) and the sequence was verified by automated
DNA sequencing. The fusion protein was purified as described
(Wang et al, 1996, 1998) and used for immunizing rabbits at 
2-week intervals. Antibody valence was determined by double
immunodiffusion test and the specificity was confirmed by
Western blotting. 
Expression of HCCA2 in transfected cells 
The full-length HCCA2 cDNA was recloned into the pcDNA3
expression vector. When human embryonic kidney fibroblast 293
cells (ATCC CRL 1573) grew to nearly 70% confluency, the cells
were transfected with 2 µ g purified plasmid of HCCA2/pcDNA3
using Profection® Mammalian Transfection Systems (Promega,
Madison, WI, USA), according to the manufacturer’s instruction.
Cells transfected with empty vector of pcDNA3 were served as
control. 72 h after transfection, the cells were washed in phos-
phate-buffered saline and lysed in Triton-X 100 lysis buffer (Wang
et al, 1996, 1998) at 4˚C. Cell lysates from HCCA2-transfected
cells and control plasmid-transfected cells were separated on a
10% polyacrylamide gel, transferred to nitrocellulose membrane
and probed with HCCA2 polyclonal antibodies (dilute in 1:2000)
for 1 h. 
Immunohistochemical staining for HCCA2 
Surgical specimens including HCC tissues and surrounding liver
tissues were fixed in 10% neutral formalin and embedded in
paraffin. 5 µ m paraffin sections were subjected to immunoperoxi-
dase staining with HCCA2 polyclonal antibodies (dilutein 1:100)
and Ki-67 antibody (Immunotech, Marseille, France) using
Immunopure staining ABC kit (Dako, Glostrup, Denmark)
according to the manufacturer’s instruction. The sections were
lightly counterstained with Harris’s haematoxylin and examined
under light microscope. 
Statistical analysis 
We used the χ 2 test or the Fisher’s exact test for statistical analysis.
A P of less then 0.05 was considered significant. 
RESULTS 
Cloning and sequencing of HCCA2 cDNA 
In DDPCR analysis, we identified a candidate band that was
expressed preferentially in HCC. This fragment (length in 582
base pairs) was then subcloned into pGEM-T vector and served as
specific probe to screen a human placental cDNA library. The full-
length cDNA of 2520 base pairs (bp) was cloned from a human
placental cDNA library. The cDNA sequence that was designated
HCCA2 (hepatocellular carcinoma-associated gene 2) was
submitted to EMBL/GenBank/DDBJ nucleotide sequence data-
bases (Accession No. AF206328). HCCA2 contains a consensus
initiation codon (Kozak, 1989) at position 891 followed by a
single open reading frame of 1401 bp encoding 467 amino acids.
The 3′ untranslated region of 202 bp had a consensus polyadenyla-
tion signal (AATAAA) beginning at the 19th base upstream of the
poly (A) tail. Alignment at nucleotide and amino acid level
showed no significant homologues with known genes. The
deduced protein was estimated to be 50.65 kDa and had a pI of
8.14. Amino acid sequence analysis by GCG sequence analysis
software package (version 9.1, Genetics Computer Group,
Madison, Wisconsin) and PC/GENE (Version 5.03, Geneva
University, Switzerland) showed that there were several putative
modification sites. These include 2 N-glycosylation sites at amini
acid of 71 and 441 and 6 N-myristoylation sites at amini acid of
70, 187, 285, 337, 408 and 435. Additionally, there were numerous
phosphorylation sites for protein kinase: 2 cAMP- and cGMP-
dependent protein kinase phosphorylation sites at amino acid of
127 and 248, 2 protein kinase C phosphorylation sites at 248 and
278 and 6 casein kinase II phosphorylation sites at 54, 154, 189,
346, 347 and 444. No transmembrane domain and signal peptide
and nuclear targeting sequence were found. The HCCA2 protein
was enriched in proline residues, and had 2 Src homology 3 (SH3)-
binding domains (Cohen et al, 1995; Kang et al, 2000). 
Expression of HCCA2 mRNA in adult and fetal tissues 
Northern blot analysis showed that HCCA2 mRNA appears to be
widely expressed in adult tissues (Figure 1). The HCCA2 gene














Figure 1 Northern blot analysis of HCCA2 mRNA in human adult normal
tissues. Upper panel showed HCCA2 mRNA was intensively expressed in
human small intestine, muscle, lung, pancreas, brain, stomach, spleen, colon
and heart tissue, but not expressed in liver tissues. The main transcript was
2.5 kb in length, whereas 1.8 kb transcript also could be observed. To show
the relative quantities of loaded RNAs, the blot was rehybridized with β -actin
cDNA probe (lower panel) Expression of HCCA2 in hepatocellular carcinoma 1165
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muscle, lung, pancreas, brain, stomach, spleen, colon and heart
tissues, but not expressed in liver tissues. HCCA2 mRNA was
detected in abundance in fetal liver (2 of 2 fetuses), lung (2 of 2
fetuses), brain (2 of 2 fetuses), and spleen (2 of 2 fetuses) (data not
shown). Among all the adult and fetal tissues with positive signals,
HCCA2 mRNA was observed in 2 transcripts: one was approxi-
mately 2.5 kb, which well corresponded to the size of the cloned
cDNA, and the other about 1.8 kb. 
HCCA2 mRNA expression in HCC and its clinical
significance 
Among various adult tissues examined, HCCA2 mRNA was not
detected in normal hepatic tissues. However, it intensively
expressed in HCC tissues (Figure 2). HCCA2 mRNA expression
was detected in 79% (34/43) of patients and was absent in 21%
(9/43). All of them showed significantly high expression of
HCCA2 mRNA in HCC tissues while no expression in
surrounding liver tissues (except that HCCA2 mRNA was
detected in low levels in only 2 cases of surrounding liver tissues).
HCCA2 mRNA expression correlated closely with the invasion of
liver cancer capsule (P = 0.0007) and the expression of Ki-67
protein (P = 0.0022), but that was not related to tumour size,
tumour differentiation, serum AFP, HBsAg seropositivity, micro-
scopic vascular cancer cell thrombi and adjacant small satellite
nodules lesions (P > 0.05). 
Overexpression of HCCA2 in mammalian cells 
After transfection, the full length of HCCA2 cDNA was tran-
siently overexpressed in the human embryonic kidney fibroblast
293 cells. Using antiserum of HCCA2 for immunoblot analysis, a
protein of approximately 50 kDa was recognized in transfected
cells which neared the calculated size of 50.65 kDa. This band was
not detected in cells transfected with an empty expression vector
(Figure 3). 
Immunohistochemical assay 
Immunostaining showed that HCCA2 protein was expressed in
HCC tissues only, and it was localized in the cytoplasm (Figure 4).
Among 43 patients examined, 11 (25.6%) revealed positive
staining with HCCA2 antibody. The positive staining of Ki-67
protein was localized in the tumour cell nucleus, not expressed in
surrounding liver. The positive expression rate of Ki-67 protein
was 76.7% (33/43). 
DISCUSSION 
Using a mRNA DD technique (Liang and Pardee, 1992; Liang
et al, 1993), we have successfully isolated and characterized a full-
length cDNA named HCCA2 with a transcript of 2520 bp
(European Molecular Biology Laboratory/GenBank/DNA Data
Bank of Japan accession no. AF206328). The HCCA2 mRNA
















Figure 2 Northern blot analysis of HCCA2 of paired HCC (H) and nontumour
liver (L) tissues. A signal transcript of 2.5 kb was shown in 6 tumours (upper
panel). Equal amount of total RNA loading as indicated by rehybridizing with







Figure 3 Western blot analysis of HCCA2. Blot was probed with rabbit
polyclonal antiserum against HCCA2. The antiserum of HCCA2 recognized a
protein of approximately 50 kDa protein in human embryonic kidney 293 cells
transfected with full-length HCCA2 expression construct (lane 2), but not in
control plasmid-transfected cells (lane 1). Molecular size markers are
indicated in kDa. 
Figure 4 Immunohistochemistry analysis showed that HCCA2 was
expressed in hepatocellular carcinoma cells. The immunoreactivity oriented
in liver cancerous cells and localized in cytoplasm. No signals were found in
surrounding liver nontumour hepatocytes. Original magnification, × 300 1166 Z-X Wang et al 
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protein of 467 amino acids containing no apparent signal peptide,
transmembrane domain and nuclear targeting sequence. A smaller
transcript of about 1.8 kb was identified in human adult and fetal
tissues. The HCCA2 nucleotide and amino acid sequence showed
no significant homologues with known genes. The HCCA2 protein
is a proline-rich protein, because there were 62 prolines in 467
amino acids. The presence of 2 SH3 binding-domains indicates
that the HCCA2 protein might have an important function in cell
signal transduction (Cohen et al, 1995; Myllyharju and Kivirikko
1999; Nagasaki et al, 1999; Kang et al, 2000). The numerous phos-
phorylation sites may contribute to the transport of the HCCA2
protein (Graves and Krebs, 1999). The function of HCCA2 protein
may also greatly depend on its phosphorylation status and SH3-
binding domains. The immunohistochemical analysis showed that
HCCA2 protein was located in the cytoplasm, indicating that
HCCA2 is possibly a cytoplasmic protein. The predicted modifica-
tion sites of the protein may be involved in diverse regulatory
processes including intracellular signal transduction in the regula-
tion of cellular proliferation. There is evidence that deregulation of
protein phosphorylation is involved in several human cancers.
HCCA2 as a possible oncoprotein may have functional abnor-
mality and phosphorylative deregulation may be a mechanism. 
Further studies on expression of HCCA2 may indicate its poten-
tial biological significance. We found that the HCCA2 mRNA was
expressed widely in adult and fetal tissues, indicating that HCCA2
might be a normal developmentally regulated gene which was
involved in the physical process of the distributed tissues. Other
functions may also be involved. In normal adult tissues, HCCA2
was expressed in 2 transcripts of 2.5 kb and 1.8 kb, whereas in
HCC, it was observed in a signal transcript 2.5 kb. We did not
know the significance of these differences. Although HCCA2
mRNA was not detected in adult liver tissues, it was significantly
expressed in HCC tissues, indicating that the HCCA2 may be
stimulated to expression by some unknown factors in the process
of liver oncogenesis. Also it implied that HCCA2 was regulated at
transcript level in HCC. Because HCCA2 is a normal cellular
gene, increased expression of HCCA2 in HCC may have genetic
abnormality and act as an oncogene in the development of HCC.
HCCA2 mRNA was expressed in abundance in fetal liver, but the
levels became undetectable in adult liver, indicating that the
expression of HCCA2 mRNA in adults was shut off and resurged
in HCC. These findings suggest that HCCA2 is also an oncodevel-
opmental gene. In 43 patients with primary HCC, HCCA2 mRNA
was detected in 34 (79%), who had significantly high expression
in HCC tissues, but it was expressed in low levels in only 2 cases
of cirrhotic surrounding liver tissues, suggesting that HCCA2 is a
very common molecular event involved in the pathogenesis of
HCC. These finding indicate that HCCA2 mRNA is overexpressed
preferentially in HCC and can serve as a tumour biomarker for
HCC. Of the 34 patients, 3 that had macroscopic portal vein
tumour spread had significant expression of HCCA2 mRNA,
implying that HCCA2 is a later incidence in HCC carcinogenesis. 
To explore the potential biological role of HCCA2 mRNA
expression, we selected 43 patients who had unicentric primary
HCC. Of these, the expression of HCCA2 mRNA was found in 34
cases and correlated positively with the invasion of tumour capsule
(P = 0.0007) and the expression of ki-67 protein (P = 0.0022) in
HCC. It indicates that HCCA2 mRNA expression is a factor of HCC
invasiveness and proliferation (Kaita et al, 1997; Tiniakos and Brunt,
1999). Ki-67 protein is a proliferating nuclear antigen present in
replicating cells. The ability to document nuclear proliferation in the
liver is essential to our understanding of hepatic regeneration and
hepatocellular carcinoma (Kaita et al, 1997). Immunohisto-
chemistry analysis further comfirmed in protein level that HCCA2
gene is intimately connected to HCC (Kaita et al, 1997). The posi-
tive rate of HCCA2 protein is significantly lower than the mRNA
expression in tumour tissues, which may result from increased
protease-mediated degradation rather than altered gene expression
(Loda et al, 1997), or the expression level of HCCA2 protein is too
low to be easily detected by immunohistochemistry method.
Although the function of HCCA2 is still unknown, our results
suggest that this novel gene codons for a cytoplasmic protein, and
up-regulation of HCCA2 may play an important role in the devel-
opment and/or progression of hepatocellular carcinoma. Hence,
more studies are warranted to better understand the biological
functions of the HCCA2 gene. 
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